Food Allergy Drug Pipeline: Over 30 Companies, 35+ Drugs Under Review

A new market research report published in Dublin provides a comprehensive overview of the food allergy drug development landscape in 2024. The report tracks the progress of over 30 companies and more than 35 drug candidates.

The report includes detailed profiles of drugs in both clinical and non-clinical stages. Assessments cover product type, stage, route of administration, and molecule type. Additionally, the report identifies pipeline products that have been discontinued.

The research also delves into the disease overview and treatment guidelines for food allergies, offering an analysis of ongoing commercial and clinical assessments of pipeline products. For individual drugs, the report outlines their mechanism of action, clinical studies, approvals, and details on collaborations, licensing, and funding.

Several promising candidates are specifically highlighted. DBV Technologies' Viaskin Peanut utilizes epicutaneous immunotherapy (EPIT) for peanut allergy treatment. Genentech's Omalizumab, already approved for allergic asthma, is being evaluated for food allergy indications. Regeneron Pharmaceuticals is developing Dupilumab, an antibody blocking IL-4 and IL-13 signaling pathways, and Alladapt Immunotherapeutics is studying an oral immunotherapy candidate named ADP101.